Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication

NCT ID NCT07724873

Recruiting now Disease control Sponsor: Tata Memorial Centre Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a compound from the herb ashwagandha, called withaferin A, can help prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancer. GvHD is a serious complication where donated immune cells attack the recipient's body, affecting up to 60% of patients despite standard prevention. Participants will take withaferin A capsules for 90 days after transplant, alongside standard medications, to see if it safely reduces the risk of acute GvHD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a standardized root extract of Withania somnifera (ashwagandha) called withaferin A
What this could lead to
If it works, this could offer a safe, inexpensive, and easy-to-take pill to prevent a life-threatening complication of stem cell transplants, improving survival and reducing costs.
What could go wrong
This is an early-phase trial with only 54 participants, so the results may not apply broadly. Side effects like liver enzyme increases and skin rash are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD - GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD - GRAFT-VERSUS-HOST DISEASE HEMATOLOGICAL MALIGNANCY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advanced Centre for Treatment, Research and Education in Cancer

    RECRUITING

    Navi Mumbai, Maharashtra, 410210, India

  • Advanced Centre for Treatment, Research and Education in Cancer

    RECRUITING

    Navi Mumbai, Maharashtra, 410210, India

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.